About US
Contact us
-
Roche's Tecentriq scores a first-in-class double win in new liver cancer patientsRoche is out with phase 3 Tecentriq results in liver cancer, and it’s out in full force. The immuno-oncology med, in combination with fellow Roche drug Avastin, not only showed it could beat Bayer's2019/10/21
-
Gilead's ready to spend big on Descovy, filgotinib launches as hep C and Yescarta struggle: CEOIf Gilead’s investors are worried the company’s new leadership team won’t pony up to support key launches—starting with HIV drug Descovy in PrEP—they don’t need to be, according to CEO Daniel O’Day.2019/10/18
-
Has AstraZeneca finally arrived? Seems so, with oncology and China growth—at least for nowOnce again, AstraZeneca’s newer cancer drugs Tagrisso, Lynparza and Imfinzi, as well as China, have teamed up for growth. But each faces its own fight just around the corner. EGFR lung cancer drug Ta2019/10/18
-
Vertex opens up $500M in sales with landmark CF deal in EnglandA years-long cystic fibrosis drug pricingstandoff has finally yielded a deal, and now thousands of patients in the U.K. are set to access key medicines from Vertex Pharmaceuticals. Vertex and NHS Eng2019/10/17
-
J&J’s third-quarter profits take $3B hit with massive opioid settlementJust three days after pledging to kick in $4 billion of a whopping $48 billion opioid settlement reached with Ohio, Johnson & Johnson is spelling out the impact of the agreement on its bottom lin2019/10/17
-
Lilly counts on growing markets to boost lagging Taltz, TrulicityEli Lilly is counting on Type 2 diabetes drug Trulicity and immunology launchTaltzto keep rollingamid challenges elsewhere. But bothmedsmissed Wall Street'sexpectations, prompting questions from anal2019/10/16
-
Lilly USA, diabetes chief Enrique Conterno bows out after 27 yearsEli Lilly's top U.S. executive is on the way out. Enrique Conterno, who heads up Lilly's worldwide diabetes business as well as Lilly USA, is retiring after 27 years at the company. Mike Mason, himse2019/10/16
-
Amgen CFO David Meline, overseer of major restructuring, to retireIn the second half of 2014, Amgen initiated a major overhaul aimed at cutting costs and boosting R&D activities. Now, the chief financial officer tapped on the eve of the revamp is set to bid the2019/10/15
-
NHS England, Vertex cystic fibrosis drug negotiations have 'intensified,' official saysVertexPharmaceuticals and Britishhealth authorities have been stuck in cystic fibrosis (CF) drug pricing negotiations for years, and now those talks have again heated up. National Health Service (NHS2019/10/15
-
Novartis says Ireland site will lose up to 320 jobs as productivity squeeze continuesNovartis CEO Vas Narasimhan credits manufacturing “productivity programs” for helping improve company margins. That productivity tightening will play out next at operations in Ireland where up to 3202019/10/14